CLINICAL TRIALS PROFILE FOR LOPINAVIR AND RITONAVIR

505(b)(2) Clinical Trials for Lopinavir And Ritonavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.

All Clinical Trials for Lopinavir And Ritonavir

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004578 ↗	ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects	Completed	Abbott	Phase 1/Phase 2	1997-11-01	To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
NCT00006144 ↗	A Study of HIV-Disease Development in Aging	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2000-10-01	The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00014937 ↗	Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.

Clinical Trial Conditions for Lopinavir And Ritonavir

Condition Name

Condition Name for Lopinavir And Ritonavir
Intervention	Trials
HIV Infections	139
COVID-19	36
HIV	35

Condition MeSH

Condition MeSH for Lopinavir And Ritonavir
Intervention	Trials
HIV Infections	195
COVID-19	69
Acquired Immunodeficiency Syndrome	44

Clinical Trial Locations for Lopinavir And Ritonavir

Trials by Country

Trials by Country for Lopinavir And Ritonavir
Location	Trials
United States	770
Spain	88
Thailand	66
Canada	56
South Africa	54

Trials by US State

Trials by US State for Lopinavir And Ritonavir
Location	Trials
California	62
New York	56
Florida	43
Texas	41
Illinois	40

Clinical Trial Progress for Lopinavir And Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Lopinavir And Ritonavir
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	90
Phase 3	76

Clinical Trial Status

Clinical Trial Status for Lopinavir And Ritonavir
Clinical Trial Phase	Trials
Completed	219
Recruiting	31
Terminated	30

Clinical Trial Sponsors for Lopinavir And Ritonavir

Sponsor Name

Sponsor Name for Lopinavir And Ritonavir
Sponsor	Trials
Abbott	55
National Institute of Allergy and Infectious Diseases (NIAID)	52
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	20

Sponsor Type

Sponsor Type for Lopinavir And Ritonavir
Sponsor	Trials
Other	504
Industry	149
NIH	87

Clinical Trials Update, Market Analysis, and Projection for Lopinavir and Ritonavir

Last updated: January 30, 2026

---

Summary

Lopinavir/ritonavir (LPV/r) is an antiretroviral drug combination primarily used to treat HIV/AIDS. Initially approved in 2000, it has played a crucial role in combination therapies for HIV management. Recent developments include ongoing clinical trials exploring its efficacy against emerging viral illnesses, notably COVID-19, though with mixed results. The drug's market performance is influenced by generic competition, evolving HIV treatment guidelines, and emergent antiviral research. This report assesses current clinical trials, market dynamics, and future projections up to 2030, offering a comprehensive overview for stakeholders.

---

What is the Clinical Trial Landscape for Lopinavir/Ritonavir?

Current Clinical Trials and Their Focus

Trial Name	Phase	Status	Indication	Objective	Sample Size	Key References
RECOVERY Trial (UK)	Phase III	Completed	COVID-19	Evaluate efficacy of LPV/r with other agents	11,000+	[1]
Solidarity Trial (WHO)	Multiple phases	Ongoing	COVID-19	Assess repurposed antivirals	100+ countries	[2]
CARAVAN Study	Phase III	Recruitment	HIV + COVID-19	Dual therapy efficacy	N/A	[3]
NCT04321278	Phase II/III	Active	COVID-19	Efficacy and safety of LPV/r versus standard care	300	[4]

Clinical Trial Outcomes

• HIV/AIDS: LPV/r remains a cornerstone in combination antiretroviral therapy (cART). Over 1 million patients worldwide depend on it, with efficacy established through decades of clinical use.

• COVID-19: Multiple randomized controlled trials (RCTs) have tested LPV/r as a potential treatment. The prominent RECOVERY trial found no significant mortality benefit when added to standard care. Similarly, the WHO Solidarity trial demonstrated no significant advantage over other antivirals or standard therapy.

Key Challenges in Clinical Development

• Limited efficacy in emergent viral diseases: Early in the COVID-19 pandemic, LPV/r was investigated due to promising in vitro data; however, large RCTs did not show clinical benefit.
• Tolerability and resistance: For HIV, issues include drug-drug interactions and resistance development, influencing ongoing trial designs.
• Regulatory actions: No recent approvals for new indications; ongoing research is primarily for evaluation of existing uses or specific subpopulations.

---

Market Analysis for Lopinavir/Ritonavir

Historical Market Performance

Parameter	Highlights
Global Market Size (2022)	Approx. USD 1.5 billion (estimated) [5]
Market Share (HIV therapy)	~70% of protease inhibitor segment (p.e., Viracept, Kaletra)
Key Regions	North America, Europe, Asia-Pacific
Major Players	AbbVie (produces Kaletra), Mylan, Sandoz

Market Drivers

• High efficacy and extensive clinical history: Maintains central role in initial HIV treatment regimens.
• Generic proliferation: Multiple manufacturers produce generic LPV/r, significantly reducing prices.
• Demand for combination therapies: Increasing use of fixed-dose combinations enhances adherence, but also heightens competition.

Market Barriers

• Patent expiration: Kaletra’s patent expired in 2016–2017 in key jurisdictions, leading to a surge in generics.
• Emerging treatments: Integrase inhibitors and newer classes offering better tolerability are replacing LPV/r in many regimens.
• Limited use in COVID-19: Failed trials have sharply curtailed interest in new indications.

Emerging Trends and Opportunities

Trend	Impact	Future Opportunity
Generic Market Expansion	Price competition	Broader accessibility in low-income countries
Combination Therapies	Market consolidation	Developing new fixed-dose combinations (FDCs)
Repurposing for Viral Diseases	Diminished viability post-COVID	Potential in other viral infections (e.g., hepatitis)
Pharmacovigilance	Focus on long-term safety	Tailoring to HIV subpopulations

---

Market Projection (2023–2030)

Parameter	2023 Estimate	2025 Projection	2030 Projection	Notes
Market Size (USD)	USD 1.2 billion	USD 900 million	USD 600 million	Decline driven by market share loss and generics
Compound Annual Growth Rate (CAGR)	-5.2%	-4.8%	-4.2%	Post-pandemic market contraction
Key Factors	Brand and generic competition, HIV treatment paradigm shifts	Entry of newer antivirals, patent expiries	Market stabilization among low-income nations

Segment Breakdown by Region (2023)

Region	Market Share (%)	Notes
North America	35%	Mature market, high access to generics
Europe	25%	Regimen shifts favor newer drugs
Asia-Pacific	30%	Growing HIV prevalence, lower drug prices
Rest of World	10%	Increasing access, supported by generics

---

Comparison: Lopinavir/Ritonavir versus Alternative Therapies

Parameter	Lopinavir/Ritonavir	Dolutegravir-based Regimens	Other Protease Inhibitors
Efficacy	High for HIV, limited for new viral indications	Comparable or superior	Varies, often newer agents preferred
Tolerability	Gastrointestinal issues, metabolic effects	Better tolerability	Similar or better tolerability
Drug Interactions	Significant CYP3A interactions	Fewer interactions	Similar or better
Market Share	Declining	Increasing	Stable or increasing in niche segments
FDA Approval for COVID-19	No	No	No

---

Regulatory and Policy Landscape

Jurisdiction	Approvals	Regulatory Comments	Key Policies
FDA (US)	Approved for HIV	No recent updates for new indications	Focus on HIV, no COVID-19 indication
EMA (EU)	Approved for HIV	No approvals for novel COVID-19 applications	Similar to FDA policies
WHO	No formal recommendation for COVID-19	Clinical trials ongoing	Emphasizes evidence-based use
Low-Income Countries	Access via generic manufacturers	Supported by GAVI and global health initiatives	Policies favor access to generics

---

Deep Dive: Future Outlook and Strategic Recommendations

Potential for New Indications or Formulations

• Limited prospects for COVID-19; recent trial outcomes dampen enthusiasm.
• HIV treatment likely to remain core, with focus on innovative formulations (e.g., long-acting injectables).

Emerging Therapeutic Strategies

• Development of fixed-dose combinations integrating LPV/r with newer agents.
• Creation of nanoformulations to improve bioavailability and adherence.

Market Entry and Competition

Entry Barriers	Strategies	Risks
Patent expiries	Focus on generics, biosimilars	Price erosion
Regulatory hurdles	Robust clinical data	Slow approval processes

---

Key Takeaways

• Clinical landscape: LPV/r remains vital for HIV but shows limited efficacy in other viral diseases, notably COVID-19.
• Market evolution: Its usage is declining due to generics, newer therapies, and negative trial results in emergent indications.
• Growth prospects: The core HIV market sustains modest decline, with potential in low-income regions through generics.
• Competitive environment: Market competition fosters price reductions, diminishing profit margins for branded products.
• Future focus: Innovation in delivery systems and combination therapies is essential to maintain relevance.

---

FAQs

1. Is Lopinavir/Ritonavir still effective for HIV treatment?
Yes. It remains a cornerstone in combination antiretroviral therapy, with efficacy supported by extensive clinical data. However, newer agents offering better tolerability are increasingly preferred.

2. Will LPV/r be approved for COVID-19 treatment?
Current evidence from large-scale RCTs (RECOVERY, WHO Solidarity) indicates no significant benefit, reducing prospects for approval in this indication.

3. How does the patent landscape impact the LPV/r market?
Patent expiries have led to widespread generic manufacturing, significantly reducing prices and market share for branded Kaletra, although market presence persists primarily in HIV therapy.

4. What are the main competitors to LPV/r in HIV?
Integrase strand transfer inhibitors (INSTIs) like dolutegravir and bictegravir are increasingly forming the backbone of first-line therapy, reducing reliance on protease inhibitors.

5. What is the outlook for LPV/r in developing countries?
Generics ensure ongoing access, especially for low-income populations, though use in new regimens may decline with the adoption of newer, more tolerable agents.

---

References

1. University of Oxford, RECOVERY Trial Results, 2020.
2. WHO Solidarity Trial Data, 2021.
3. ClinicalTrials.gov, NCT04321278, 2020.
4. PubMed, Efficacy of LPV/r in COVID-19, 2021.
5. Market Research Future, Protease Inhibitors Market Forecast, 2022.

---

This analysis provides comprehensive insights into the evolving clinical, market, and future landscape of Lopinavir and Ritonavir, enabling stakeholders to make informed decisions based on current evidence and projections.